NICE proposes Mabthera use in additional chemo regimes
This article was originally published in Scrip
Executive Summary
New draft guidance from the National Institute for Health and Clinical Excellence (NICE), the health technology agency for England and Wales, is proposing that Mabthera (rituximab) should be available in combination with a wider range of chemotherapy regimens to National Health Service patients with symptomatic stage III and IV follicular lymphoma. Stakeholders are invited to comment on the appraisal consultation document between 5 and 26 September, 2011 (www.nice.org.uk/guidance/index.jsp?action=article&o=56199).